TNFRSF17/BCMA
Alpha Lifetech can provide TNFRSF17/BCMA corresponding products, help each customer's research and development.
01
Introduction To TNFRSF17/BCMA
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to TNFRSF17/BCMA is a common target in medicine.
BCMA, the B cell mature antigen also called TNFRSF17/BCMA/CD269, is a member of the tumor necrosis factor receptor superfamily, and was first discovered in the early 1990s. It is a single transmembrane glycoprotein with 184 amino acids and plays a major role in the maturation and differentiation of B cells into plasma cells (PCs, plasma cells). It is encoded by the 2.92-kb TNFRSF17 gene, which consists of three exons and 2 introns. BCMA, an 184 amino acid type 20.2kDa transmembrane glycoprotein with a conserved motif of six cysteines at the extracellular N terminal end, is a member of the tumor necrosis factor receptor (TNFR) superfamily. There are four natural splice variants of human BCMA with different receptor binding affinity, membrane anchoring ability, and intracellular domain signals. In normal human tissues, BCMA protein and mRNA are found almost exclusively in the plasma cells and are selectively overexpressed during the malignant transformation of the plasma cells.
Function of Target TNFRSF17/BCMA
BCMA is important for the survival of long-lived plasma cells, but it appears relatively minor for the maintenance of normal B cell homeostasis. This property makes BCMA a key target for the treatment of plasma cell malignant proliferative diseases such as multiple myeloma. BCMA affects the proliferation, differentiation, and survival of plasma cells by participating in cell signaling. In multiple myeloma, the abnormally high expression of BCMA promotes the proliferation and survival of malignant plasma cells, thus driving the disease progression.
Gene Pathway of Target TNFRSF17/BCMA
BCMA protein and mRNA are found almost exclusively on plasma cells and are selectively overexpressed during malignant transformation of plasma cells, promoting tumor cell growth, survival and drug resistance, mainly through the activation of NFᴋB, AKT, phosphatidylinositol 3 kinase (PI3K), STAT 3, and MAPK cell signaling cascades. The binding to the BCMA receptor interferes with BAFF and APRIL signaling to induce ADCC, while the cytotoxic components can inhibit cell division by blocking microtubule polymerization, arrest tumor cells at G / M phase and induce caspase-3-dependent apoptosis.
Fig 1: BCMA Gene Pathway. (Reference source: Tai YT, Anderson KC. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma. Expert Opin Biol Ther. 2019 Nov;19(11):1143-1156.)
Alpha Lifetech Can Provide
Currently, various immune drugs targeting TNFRSF17/BCMA targets are in the updating iteration, and taking the disease alone or in combination with other products has become a new approach with remarkable achievements. TNFRSF17/BCMA targets have shown important research value and application prospects in both biology and drug research and development. With further research and detection technology advances, TNFRSF17/BCMA target products are also essential in medical research.Alpha Lifetech can provide TNFRSF17/BCMA corresponding products and help each customer's research and development. In addition, Alpha Lifetech also provides advanced expression systems and purification services to accelerate antibody research and development. Our synthesized antibody expression undergoes rigorous quality validation, including sequencing validation and functional expression analysis, to ensure high fidelity and performance. In addition, Alpha Lifetech provides customized solutions for recombinant proteins, such as codon optimization, promoter selection, and vector design, supplemented by downstream applications such as protein expression analysis to meet specific experimental needs.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ALP64702 | 50ug,100ug,500ug | |
| ALP64524 | 50ug,100ug,500ug | |
| ALP64513 | 50ug,100ug,500ug | |
| ALP64511 | 50ug,100ug,500ug | |
| ADT1078 | 1mg,5mg | |
Reference
[1] Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020 Sep 17;13(1):125.
[2] Tanabe H, Ishida T, Ueda S, Sofuni T, Mizusawa H. Comparative mapping of the immunoglobulin C epsilon 1 gene (IGHE) in five species of nonhuman primates by fluorescence in situ hybridization. Cytogenet Cell Genet. 1995;70(3-4):239-42.
[3] Wagner B. IgE in horses: occurrence in health and disease. Vet Immunol Immunopathol. 2009 Nov 15;132(1):21-30.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102